

**J. B. CHEMICALS & PHARMACEUTICALS LIMITED**

REGD. OFFICE:

"NEELAM CENTRE", B WING, 4TH FLOOR,
HINDI CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 2212 2482 / 2493 0918

FAX : 022 2493 0534 / 2493 9603

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1978PLC019380

StockExchange-NSE letters/MM:SA:508

November 10, 2014

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Unaudited Financial Results for the quarter ended on September 30, 2014.

Enclosed please find unaudited financial results for the quarter ended on September 30, 2014. These financial results have been approved and taken on record by the board of directors at its meeting held today.

We request you to take the above on record.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta

Company Secretary - General Manager



J. H. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

NEW CENTRAL, B WING, 4TH FLOOR

HILL, POLE ROAD, WORLI,

MUMBAI - 400 030.

PHONE : 022-2482 2992 / 2493 0918

FAX : 022-2483 0534 / 2493 9631

e-mail : info@jbcpl.com


Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30/09/2014

Sl.No.	PART I - Particulars	Quarter ended			Half Year		Year ended
		30-09-14	30-06-14	30-09-13	30-09-14	30-09-13	31-03-14
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	a. Net sales (Net of excise duty)	27,486.10	25,671.71	24,743.97	53,157.31	47,660.63	93,443.47
	b. Other Operating Income	539.67	589.07	574.68	1,128.74	1,180.81	2,209.92
	Total Income from Operations (Net) (a+b)	28,025.77	26,260.28	25,318.65	54,286.05	48,841.44	95,653.39
2	Expenses						
	a. Cost of materials consumed	8,703.83	8,338.64	7,834.52	17,042.47	15,659.87	31,078.57
	b. Purchases of stock in trade	3,070.88	2,402.03	1,584.97	5,472.91	3,824.06	7,677.06
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(507.40)	437.46	43.87	(69.94)	(163.66)	(1,074.92)
	d. Employees benefits expense	3,553.23	3,718.27	3,306.69	7,271.50	6,696.70	13,184.59
	e. Depreciation and amortization expense	1,001.00	990.00	750.00	1,991.00	1,900.00	2,716.51
	f. Exchange Fluctuation Transactional (Gain)/Loss	25.97	(49.45)	131.58	(23.48)	135.16	479.79
	g. Other Expenses	7,422.79	6,578.02	7,514.08	14,000.81	13,747.45	29,299.51
	Total Expenses	23,270.30	22,414.97	21,165.61	45,683.27	41,399.58	83,360.61
3	Profit from Operations before Other Income, Finance Cost and exceptional item (1-2)	4,755.47	3,845.31	4,153.04	8,602.78	7,441.86	12,292.78
4	Other Income	520.52	173.96	680.86	694.48	832.38	3,753.77
5	Profit from Ordinary Activities before Finance Cost and exceptional item (3+4)	5,275.99	4,019.27	4,833.90	9,297.26	8,274.24	16,046.55
6	Finance Cost	225.40	132.57	189.87	357.97	336.75	612.70
7	Profit from Ordinary Activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	5,050.59	3,886.70	4,644.02	8,939.29	7,937.49	15,433.85
8	Exchange Fluctuation Translation Gain / (Loss)	(782.29)	368.77	(617.48)	(413.52)	(1,161.64)	414.93
9	Profit from Ordinary Activities after Exchange Fluctuation Translation Gain / (Loss) but before Exceptional item (7+8)	4,268.30	4,255.47	4,026.54	8,525.77	6,775.85	15,848.78
10	Exceptional item: Revision of purchase price in respect of Sale of Russia CIS OTC Business Undertaking	-	-	-	-	-	(6,450.00)
11	Profit before Tax (9-10)	4,268.30	4,255.47	4,026.54	8,525.77	6,775.85	9,398.78
12	Tax expenses	1,079.57	1,076.37	712.27	2,155.94	1,429.03	2,556.23
13	Net Profit for the period from Ordinary Activities after Tax (11-12)	3,188.72	3,179.10	3,314.27	6,369.83	5,346.82	6,842.55
14	Paid Up Equity Share Capital (Face Value Rs. 2/-)	1,696.16	1,695.40	1,694.24	1,696.16	1,694.24	1,694.63
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	103,086.53
16	(i) Earning per share (EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	3.76	3.75	3.91	7.51	6.31	8.08
	(2) Diluted	3.76	3.75	3.91	7.51	6.31	8.07

Sl. No.	PART II - Particulars	Quarter ended			Half Year		Year ended
		30-09-14	30-06-14	30-09-13	30-09-14	30-09-13	31-03-14
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of Shares	37,501,697	37,453,963	37,385,603	37,501,697	37,385,603	37,405,427
	- Percentage of shareholding	44.22	44.18	44.13	44.22	44.13	44.15
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	47,306,528	47,315,787	47,326,197	47,306,528	47,326,197	47,326,198
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.78	55.82	55.87	55.78	55.87	55.85

**J. B. CHEMICALS & PHARMACEUTICALS LIMITED**

REG. OFFICE:

NRI CENTRE, 'B' WING, 4TH FLOOR,

HINDUSTAN ROAD, WORLI,

MUMBAI - 400 030.

PHONE : 022-2493 2222 / 2493 0918

FAX : 022-2493 0534 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

StockExchange-NSE letters/MM:SA:509

November 10, 2014

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Press Release

Enclosed is a press release we propose to issue on unaudited financial results for the quarter ended on September 30, 2014.


Kindly take the same on record.

Thanking you,

Yours faithfully,
for J.B. Chemicals & Pharmaceuticals Limited

M. C. Mehta
Company Secretary - General Manager

Encl: As above



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REG. OFFICE:

"NEELAM CENTRE", B WING, 4TH FLOOR,

HINDUSTAN CYCLE ROAD, WORLI,

MUMBAI - 400 030.

PHONE : 022-2493 2222 / 2493 0418

FAX : 022-2493 6534 / 2493 9630

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1978PLC019380

Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, November 10, 2014:

Unaudited Financial Results for Q 2- 2014-15


J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on September 30, 2014. The company posted satisfactory performance during the quarter. The highlights of Y-o-Y results are as under:

Particulars	(Rs. in crores)	
	Q2-2014-15	Q2-2013-14
Net Sales	274.86	247.44
Other Operating income	5.40	5.75
Other Income	5.20	6.80
Total Revenue	285.46	259.99
Profit from ordinary activities after finance cost but before exchange fluctuation translation loss	50.51	46.44
Profit from ordinary activities before tax	42.68	40.27
Profit from ordinary activities after tax	31.89	33.14
EPS (Rs.) (FV 2)	3.76	3.91

The net sales for the quarter at Rs. 274.86 crores were 11% higher against net sales in the corresponding quarter in the previous year. However, this is strictly not comparable Y-o-Y due to commencement of sales and distribution in Russia & CIS countries by the wholly owned subsidiary company during Q1. The profit from operations before finance cost and depreciation at Rs. 62.77 crores was 12% higher against the same quarter in the previous year.

The domestic formulations business at overall sales of Rs. 106.27 crores registered growth of 17%. The prescription products sales at Rs. 97.39 crores registered growth of 19%, while contrast media products sales at Rs. 8.88 crores registered growth of 3%. The company is fully focused on this business which has significant value potential.





J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEW AM CENTRAL", B WING, 4TH FLOOR,
HINDI CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : (022) 2482 2222 / 2493 0918

FAX : (022) 2493 0034 / 2493 9633

e-mail : info@jbcpl.com

Website : www.jbcpl.com

CIN : L24390MH1976PLC019380

The formulations exports at Rs. 129.08 crores registered growth of 7% during the quarter. The exports of formulations to Rest of the world markets at Rs. 98.28 crores registered growth of 32% in Rupee terms.

The exports for the quarter are strictly not comparable due to the company's wholly owned subsidiary in Dubai commencing sales and distribution of the products in Russia-CIS countries during the Q1. This subsidiary will also undertake some of the expenses, and hence this arrangement is not expected to have significant impact on the company. The current political situation in Russia and Ukraine has impacted sales and the company is controlling expenses to minimize the impact on bottom line. The company is observing the situation very closely for its strategy for this market.

The API business with sales for the quarter at Rs. 28.49 crores registered growth of 5%. The product development and miscellaneous sales income during the quarter amounted to Rs. 2.62 crores.

The new capex spend is progressing well.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery system and formulations, filing of DMFs and ANDAs. Its State-of-the-Art manufacturing facilities are approved by health authorities of regulated markets.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta

Company Secretary- General Manager


J. B. Chemicals & Pharmaceuticals Ltd.

91 22 24822311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.





J.B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

THE J.B. CENTRE, 'B' WING, 4TH FLOOR,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

PHONE : 022 2482 2222 / 2493 0018

FAX : 022 2493 0534 / 2493 9633

e-mail : info@jbcp.com

Website : www.jbcp.com

CIN : L24390MH1976PLC019380

B INVESTOR COMPLAINTS

Particulars	3 Months ended 30/09/2014
Pending at the beginning of the quarter	0
Received during the quarter	4
Disposed of during the quarter	4
Remaining unresolved at the end of the quarter	0

NOTES

1. The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on November 10, 2014.
2. The statutory auditors have carried out limited review of the above financial results for the quarter ended on September 30, 2014.
3. The net sales for the quarter/half year are strictly not comparable due to the company's wholly owned subsidiary in Dubai commencing sales and distribution of the products in the Russia-CIS Countries during last quarter. This subsidiary will also undertake some of the expenses. Hence this arrangement is not expected to have significant impact on the company.
4. The Company has provided depreciation based on the useful life as per Schedule II to the Companies Act, 2013.
5. The company is engaged in a single segment of activity viz. Pharmaceuticals.
6. The previous quarter's/ period's figures have been regrouped/re-stated, wherever necessary.
7. The Statement of assets and liabilities as of September 30, 2014 is as under:

Particulars	AS AT 30.09.2014	AS AT 31.03.2014
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
a. Share Capital	1,696.16	1,694.63
b. Reserves and surplus	109,139.76	103,086.53
Sub-Total of Shareholders' funds	110,835.92	104,781.16
2 Non-current liabilities		
a. Long-term borrowings	42.51	48.84
b. Deferred tax liabilities (Net)	1,818.39	1,988.93
c. Long-term provisions	1,358.70	1,218.70
Sub-Total - Non-current liabilities	3,219.60	3,256.47
3 Current liabilities		
a. Short-term borrowings	8,211.78	8,127.85
b. Trade payables	6,036.47	5,169.08
c. Other current liabilities	9,551.04	9,100.59
d. Short-term provisions	513.77	3,459.06
Sub-Total - Current liabilities	24,313.06	26,155.58
TOTAL-EQUITY AND LIABILITIES	138,368.58	134,193.21
B ASSETS		
1 Non-current assets		
a. Fixed assets	32,978.37	37,852.81
b. Non-current investments	3,951.66	3,885.67
c. Long-term loans and advances	2,022.51	1,061.99
Sub-Total - Non-current assets	38,952.54	37,800.47
2 Current assets		
a. Current investments	51,412.78	49,725.74
b. Inventories	11,697.17	11,127.70
c. Trade receivables	26,565.48	24,805.15
d. Cash and cash equivalents	1,259.31	1,080.30
e. Short-term loans and advances	8,481.30	9,658.85
f. Other current assets		
Sub-Total - Current assets	99,416.04	96,392.74
Total-Assets	138,368.58	134,193.21

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai

Date : November 10, 2014


J.B. Moday
Chairman & Managing Director

